PROCEPT BioRobotics Corporation $PRCT Holdings Boosted by Aberdeen Group plc

Aberdeen Group plc raised its stake in PROCEPT BioRobotics Corporation (NASDAQ:PRCT – Free Report) by 88.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 125,700 shares of the company’s stock after purchasing an additional 58,893 shares during the period. Aberdeen Group plc’s holdings in PROCEPT BioRobotics were worth $2,290,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of PRCT. BlackRock Inc. bought a new position in shares of PROCEPT BioRobotics during the 2nd quarter worth about $109,961,000. Wellington Management Group LLP raised its position in shares of PROCEPT BioRobotics by 47.9% during the second quarter. Wellington Management Group LLP now owns 1,274,004 shares of the company’s stock valued at $28,767,000 after buying an additional 412,399 shares during the last quarter. Jupiter Topco LLC acquired a new position in shares of PROCEPT BioRobotics during the second quarter valued at about $24,914,000. William Blair Investment Management LLC bought a new stake in shares of PROCEPT BioRobotics in the second quarter valued at about $16,020,000. Finally, Bank of America Corp DE lifted its stake in shares of PROCEPT BioRobotics by 46.3% in the first quarter. Bank of America Corp DE now owns 630,689 shares of the company’s stock valued at $15,774,000 after buying an additional 199,484 shares during the period. 89.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other PROCEPT BioRobotics news, insider Pooja Sharma sold 4,710 shares of the company’s stock in a transaction on Friday, November 6th. The stock was sold at an average price of $19.71, for a total transaction of $92,834.10. Following the transaction, the insider owned 106,471 shares of the company’s stock, valued at approximately $2,098,543.41. This represents a 4.24% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 5,753 shares of company stock worth $114,685 in the last quarter. 4.00% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on PRCT. Piper Sandler upgraded PROCEPT BioRobotics to a “strong-buy” rating in a research note on Friday, October 16th. Robert W. Baird set a $20.00 price objective on PROCEPT BioRobotics in a research report on Wednesday, August 5th. Evercore set a $23.00 price objective on PROCEPT BioRobotics in a report on Wednesday, August 5th. TD Cowen lowered their price objective on PROCEPT BioRobotics from $34.00 to $28.00 and set a “buy” rating on the stock in a research report on Wednesday, August 5th. Finally, Wall Street Zen upgraded PROCEPT BioRobotics from a “sell” rating to a “hold” rating in a research note on Saturday, November 7th. Three research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $25.25.

Read Our Latest Analysis on PRCT

PROCEPT BioRobotics Price Performance

Shares of PRCT stock opened at $24.70 on Friday. PROCEPT BioRobotics Corporation has a 52 week low of $16.67 and a 52 week high of $38.11. The stock has a market capitalization of $1.42 billion, a PE ratio of -12.23 and a beta of 0.88. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.73 and a current ratio of 5.89. The stock’s fifty day moving average is $19.87 and its 200-day moving average is $22.84.

PROCEPT BioRobotics (NASDAQ:PRCT – Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.07). The company had revenue of $98.29 million for the quarter, compared to the consensus estimate of $100.52 million. PROCEPT BioRobotics had a negative return on equity of 33.23% and a negative net margin of 32.60%. The firm’s revenue was up 18.0% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.38) EPS. Equities research analysts expect that PROCEPT BioRobotics Corporation will post -1.74 EPS for the current fiscal year.

PROCEPT BioRobotics Profile

(Free Report)

PROCEPT BioRobotics develops and commercializes surgical robotic systems for urology, with a focus on treating benign prostatic hyperplasia, or BPH, an enlargement of the prostate that can cause urinary symptoms. The company’s core offering is Aquablation therapy, delivered using its AquaBeam Robotic System. The procedure combines imaging guidance with a surgeon-controlled, robotically assisted waterjet to remove prostate tissue. PROCEPT also offers its HYDROS Robotic System, a platform designed to deliver Aquablation therapy.

Featured Stories

Want to see what other hedge funds are holding PRCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PROCEPT BioRobotics Corporation (NASDAQ:PRCT – Free Report).

Institutional Ownership by Quarter for PROCEPT BioRobotics (NASDAQ:PRCT)

Receive News & Ratings for PROCEPT BioRobotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROCEPT BioRobotics and related companies with MarketBeat.com's FREE daily email newsletter.